menu search

Viracta therapeutics announces first clinical response in epstein-barr virus-positive (ebv+) solid tumor setting and outlines key 2023 clinical objectives

Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) nasopharyngeal...

January 8, 2023, 6:00 pm

Roche's (rhhby) cancer drug glofitamab gets fda priority review

The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat ...

January 6, 2023, 12:02 pm

Molecular partners presents new preclinical data supporting its mp0533 darpin t-cell engager for the treatment of aml

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers Tri-specific T-cell engager resu...

December 13, 2022, 12:00 am

Metafora partner wugen to present data supporting clinical development of wu-nk-101 for relapsed / refractory aml at the american society of hematology's (ash) 64th annual meeting

PARIS, France & NEW ORLEANS, La.--( BUSINESS WIRE )--METAFORA biosystems announces that its partner Wugen presented data supporting clinical developme...

December 12, 2022, 3:23 pm

Adicet bio shares fall as it shares clinical data about its car-t treatment candidate

Adicet Bio's Inc. ACET, -13.13% stock tumbled about 38% in premarket trading on Monday after the company shared data from a Phase 1 clinical trial eva...

December 12, 2022, 8:47 am

Harpoon therapeutics presents updated interim results at ash 2022 for novel t cell engager hpn217 in relapsed/refractory multiple myeloma

Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with ...

December 11, 2022, 3:00 pm

Kura oncology presents updated clinical data from komet-001 trial of menin inhibitor ziftomenib at american society of hematology annual meeting

– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency ...

December 10, 2022, 3:30 pm

Sutro biopharma announces presentation of stro-002 data from the compassionate use program in pediatric patients with relapsed/refractory cbf/glis aml at ash 2022

– A total of 17 pediatric patients were treated with STRO-002 on a compassionate use basis; eight patients achieved complete remission, of which sev...

December 10, 2022, 3:30 pm

Arcellx flies on $325m deal with gilead's kite for multiple myeloma treatment

Arcellx shares soared in early trade after the clinical-stage biotechnology company announced a global strategic collaboration with Gilead Sciences' K...

December 9, 2022, 11:42 am

Syndax's (sndx) leukemia drug gets fda breakthrough therapy tag

The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with rel...

December 6, 2022, 9:47 am

Poseida therapeutics to present early data from phase 1 trials of p-muc1c-allo1 and p-bcma-allo1 at esmo immuno-oncology 2022 annual congress

P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (G...

December 6, 2022, 6:00 am

Beam up as fda lifts clinical hold on the ind for beam-201

The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed<...

December 5, 2022, 12:48 pm

Rigel (rigl) up on fda nod to blood cancer drug rezlidhia

The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid...

December 2, 2022, 2:18 pm

Rigel pharmaceuticals (rigl) stock soars on fda approval news

Rigel Pharmaceuticals (NASDAQ: RIGL ) stock is heading higher on Friday after getting approval from the U.S. Food and Drug Administration (FDA) for it...

December 2, 2022, 11:17 am

Abbvie (abbv) bla for epcoritamab gets fda priority tag

The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractor...

November 22, 2022, 7:32 am

Autolus therapeutics: near-term catalyst plus several bio deals could shift momentum

Results from the pivotal FELIX phase 2 clinical study using obe-cel for the treatment of patients with relapse...

November 16, 2022, 6:21 am

Harpoon therapeutics to present interim results from phase 1 clinical trial of t cell engager hpn217 at the 64th ash annual meeting and exposition

Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed...

November 3, 2022, 9:09 am

Innate pharma to present lacutamab ptcl phase 1b design and anket™ platform at esmo 2022

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today an...

September 5, 2022, 1:00 am

Day one biopharmaceuticals: recent strong data, and major catalysts ahead

Day One Biopharmaceuticals declared strong data in relapsed glioma in June. The company has strong cash...

September 4, 2022, 12:17 pm

Caribou biosciences: potential to change car-t landscape

Proof of concept established using CRISPR allogeneic CAR-T CB-010 for the treatment of patients with relapsed<...

August 1, 2022, 2:19 pm


Search within

Pages Search Results: